Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertension and the heart.

R E Schmieder1, F H Messerli

  • 1Department of Medicine IV, University of Erlangen-Nürnberg, Germany. roland.schmieder@rzmail.uni-erlangen.de

Journal of Human Hypertension
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urocortin 2 - a protective effect in hypertension?

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2023
Same author

In vitro fertilization exacerbates stroke size and neurological disability in wildtype mice.

International journal of cardiology·2021
Same author

More SPRINT controversy.

Journal of internal medicine·2017
Same author

Optimal blood pressure targets in 2014 - Does the guideline recommendation match the evidence base?

Hipertension y riesgo vascular·2015
Same author

Cardioprotection with beta-blockers: myths, facts and Pascal's wager.

Journal of internal medicine·2009
Same author

Beta-blockers as fourth-line therapy for hypertension: stay the course.

International journal of clinical practice·2009
Same journal

Previous COVID-19 infection: An overlooked cardiovascular risk factor.

Journal of human hypertension·2026
Same journal

Patient out-of-pocket costs for antihypertensive single pill combination products with cost caps.

Journal of human hypertension·2026
Same journal

Mindfulness based interventions for blood pressure reduction: systematic and umbrella review of existing meta-analyses.

Journal of human hypertension·2026
Same journal

Invasive observation of reactive systolic blood pressure responses to upper-arm cuff inflation.

Journal of human hypertension·2026
Same journal

Association between post-thrombectomy blood pressure trajectories and clinical outcomes in hypertensive patients with acute ischemic stroke: a retrospective cohort study.

Journal of human hypertension·2026
Same journal

Systemic inflammation indices generated from first-trimester blood tests can be potential biomarkers for predicting preeclampsia.

Journal of human hypertension·2026
See all related articles

Left ventricular hypertrophy is a significant risk factor for heart disease. Certain blood pressure medications, like ACE inhibitors, effectively reduce left ventricular mass, improving cardiovascular outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • Left ventricular (LV) hypertrophy is a key independent risk factor for cardiovascular morbidity and mortality.
  • LV hypertrophy in hypertension involves both hemodynamic and non-hemodynamic factors.
  • Regression of LV hypertrophy is a therapeutic goal, linked to reduced cardiovascular complications.

Purpose of the Study:

  • To investigate if different antihypertensive drugs vary in their efficacy for reducing LV mass.
  • To compare the effects of various drug classes on LV hypertrophy regression.

Main Methods:

  • Review of comparative studies and meta-analyses on antihypertensive drug effects on LV mass.
  • Analysis of data comparing ACE inhibitors, calcium channel blockers, beta-blockers, diuretics, and ARBs.

Related Experiment Videos

Main Results:

  • Angiotensin-converting enzyme (ACE)-inhibitors and calcium channel blockers show greater potency in reducing LV hypertrophy compared to beta-blockers.
  • Diuretics exhibit intermediate efficacy in LV mass reduction.
  • Angiotensin II AT1-receptor blockers demonstrate efficacy comparable to ACE-inhibitors, sometimes superior to beta-blockers and diuretics.

Conclusions:

  • Antihypertensive drug choice can significantly impact LV mass regression.
  • ACE inhibitors, CCBs, and ARBs are highlighted for their effectiveness in reducing LV hypertrophy.
  • Further research into drug-specific effects on LV remodeling is warranted.